Metabolic syndrome, which includes obesity, dyslipidemia, and the proinflammatory state, linked well with insulin resistance, which can be regarded as a disease with dysregulation of not only glucose homeostasis but also lipid metabolism ([@B1]).

Stearoyl-CoA desaturase (SCD) is a family of rate-limiting enzymes involved in the biosynthesis of monounsaturated fatty acids from saturated fatty acids, and its activity has been implicated in the metabolic syndrome ([@B2]). *SCD1* knockout (SCD1^−/−^) mice showed impaired triglyceride and cholesterol ester biosynthesis with increased insulin sensitivity ([@B3]). Early studies showed that the gene expression of *SCD1* was well regulated by sterol regulatory element--binding proteins (SREBPs), which are important transcription factors for the regulation of fatty acids and cholesterol metabolism ([@B4]). Insulin and glucagon act oppositely in the transcriptional regulation of hepatic SREBP-1c, with insulin inducing and glucagon repressing SREBP-1c expression ([@B5]). Constitutively expressing SREBP-1c in mice leads to increased *SCD1* expression and lipogenesis, whereas knocking out *SREBP-1c* (SREBP-1c^−/−^) results in a decreased *SCD1* expression ([@B6],[@B7]).

AMP-activated protein kinase (AMPK) functions as a sensor of cellular energy that can be activated by glucose deprivation, high AMP-to-ATP ratios, and the antidiabetes drug metformin ([@B8]). Several mechanisms of AMPK action on lipid and glucose metabolism have been studied: AMPK regulates the expression of lipid synthesis genes by modulating the activities of transcription factors and coactivators in liver and other peripheral tissues ([@B9]).

TR4 is a member of the nuclear receptor superfamily. Based on the anatomical profiling of nuclear receptor expression, TR4 was classified in the central nervous system, circadian, and basal metabolism group ([@B10]). Recent studies also indicate the rhythmic expression of *TR4* in four metabolic tissues (liver, white adipose tissue, brown adipose tissue, and muscle) over light and dark cycles ([@B11]). Using *TR4* knockout (TR4^−/−^) mice ([@B12],[@B13]) as model, we identified a novel pathway, metformin→AMPK→TR4→SCD1→insulin sensitivity, in liver that proved that TR4 may function as a regulator in lipid metabolism. Small molecules, such as metformin, AICAR, or AMPK inhibitor compound C (CpdC), are able to modulate TR4 transactivation to control the metabolic syndrome.

RESEARCH DESIGN AND METHODS {#s5}
===========================

Animal use and care. {#s6}
--------------------

All animal procedures were approved by the Animal Care and Use Committee of the University of Rochester. TR4^−/−^ male mice used in this study were generated from heterozygous breeding pairs provided by Lexicon Genetics and genotyped as previously described ([@B13]). In the fructose-feeding study, 8-week-old male TR4^+/+^, TR4^−/−^, and C57BL/6 mice were fed for 6 weeks with a fructose diet consisting of 60% fructose by weight (Dyets). Leptin receptor*--*deficient *db*/*db* mice were purchased from The Jackson Laboratory (Bar Harbor, ME).

Analytical procedures. {#s7}
----------------------

Blood was collected from fed or overnight-fasted animals, and 5--10 μL of plasma samples were used for measuring concentrations of insulin (Crystal Chem, Inc., Downers Grove, IL), free fatty acids (Wako Diagnostics, Richmond, VA), triglycerides (Sigma-Aldrich, St. Louis, MO), and glucose (LifeScan, Milpitas, CA), according to the manufacturers' protocols. For determination of tissue triglyceride content, tissue pieces (100 mg) were quick frozen in liquid nitrogen and homogenized on ice. Triglycerides were extracted from homogenized tissues with chloroform/methanol and resuspended in *t*-butyl alcohol. Resuspended samples were then mixed with Triton X-100/methanol (2:1, vol/vol) to completely dissolve the lipid suspension, and an aliquot of this solution was used for the triglyceride assay kit (Sigma-Aldrich). For determination of mitochondrial β-oxidation, the assay uses the incubation with \[^14^C\]palmitate with or without potassium cyanide followed by trapping released ^14^CO~2~ by base, as described previously ([@B14]).

Protein dephosphorylation. {#s8}
--------------------------

Cell lysates were prepared, and protein concentrations were quantified by the Bradford method (Bio-Rad, Hercules, CA). The lysates were suspended in 1 × NE Buffer (1 µg/10 µL; New England Biolabs, Ipswich, MA), and 1 unit/µg protein lysates of calf intestinal alkaline phosphatase (CIP; New England Biolabs) was added and incubated at 37°C for 60 min.

Western blot analysis. {#s9}
----------------------

Protein extracts from cell and liver tissue samples were prepared by homogenizing the tissue in modified lysis buffer. Protein samples (60 μg) were tested for TR4, SCD1, or AMPK phosphorylation levels by Western blot analyses. Western blotting was performed with anti-TR4, anti-SCD1 (Alpha Diagnostic International, San Antonio, TX), anti--phospho-AMPK (Cell signaling), or anti-α1AMPK antibodies (Cell Signaling Technology, Danvers, MA) ([@B15]).

Determination of gene expression. {#s10}
---------------------------------

Total RNA was isolated from different tissues using TRIzol reagent (Invitrogen, Carlsbad, CA), and cDNA was synthesized using SuperScript II and random hexamer primers (Invitrogen). Quantitative RT-PCR was performed using SYBR green supermix reagent with the iCycler real-time PCR amplifier (Bio-Rad). The results are given as percentage over control after normalization of mRNA to 18S rRNA expression. A list of primer sequences for real-time PCR is available in [Supplementary Table 1](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db10-0393/-/DC1).

Reagents, plasmids, and luciferase assay. {#s11}
-----------------------------------------

We used 500 μmol/L metformin (Sigma-Aldrich), 1 mmol/L AICAR (Calbiochem, San Diego, CA), and 10 μmol/L CpdC (Dorsomorphin; Calbiochem). The plasmid pCMX-TR4 has been described previously ([@B15]). The human SCD1 5′ promoter region consisting of −487 to +67 bp was amplified by PCR from HepG2 genomic DNA and cloned into pGL3 reporter vector (Promega, Madison, WI) to generate pGL-SCD-Luc. Deleted pGL-SCD1 (−237/+67)-Luc containing −237 to +67 bp of SCD1 5′ promoter region was generated by PCR amplification from pGL-SCD1-Luc and subcloning into pGL3 (Promega). The DR1 × 3-Luc plasmid contains three copies of the TR4- response element (TR4RE) direct repeat (DR) ([@B15]). Hepa1--6, HepG2, and COS-1 cells were maintained in Dulbecco's modified Eagle's medium containing 10% FCS. Transfections were performed by using SuperFect (Qiagen, Valencia, CA). Relative luciferase activities were measured in the luciferase reporter assay system (Promega). The plasmid pRL-TK (Promega) for internal control was cotransfected in all transfection experiments.

Glucose and insulin tolerance tests. {#s12}
------------------------------------

For the glucose tolerance test, mice were fasted overnight, followed by an intraperitoneal [d]{.smallcaps}-glucose injection (2 g/kg body wt). Blood glucose was measured by tail bleeding at 0, 15, 30, 60, and 120 min after the injection. For the insulin tolerance test, mice were injected intraperitoneally with human insulin (Sigma-Aldrich) at 1 unit/kg body wt, and blood glucose was measured at 0, 15, 30, and 60 min after the administration.

Histological analysis. {#s13}
----------------------

Tissues were fixed in fresh 4% buffered paraformaldehyde and then dehydrated through a series of graded alcohols before being embedded in paraffin. Tissue sections were stained with hematoxylin and examined under light microscopy. To investigate the lipid amount in both TR4^+/+^ and TR4^−/−^ livers, Oil Red O staining was performed ([@B16]).

Chromatin immunoprecipitation assay. {#s14}
------------------------------------

Chromatin immunoprecipitation (ChIP) assays were performed in HepG2 cells, as described in previous studies ([@B12]). Immunoprecipitations were performed at 4°C overnight, with 2 µg TR4 antibody number 15. The list of primers used can be found in [Supplementary Table 1](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db10-0393/-/DC1).

Statistical analysis. {#s15}
---------------------

Experiments were carried out at least in duplicate and repeated three times. The result was expressed as means ± SD. The *P* values calculated from the Student *t* test and one-way ANOVA \<0.05 are interpreted as statistically significant.

RESULTS {#s16}
=======

AMPK phosphorylates hepatic TR4 at the serine 351 site. {#s17}
-------------------------------------------------------

Using peptide mapping and motif scan, we found that the amino acid serine 351 (Ser351) phosphorylation site, which is conserved in human, mouse, and rat TR4, is a potential target of AMPK ([Fig. 1*A*](#F1){ref-type="fig"}). We used SDS-PAGE analysis to examine the TR4 phosphorylation status in mouse hepatocyte Hepa1--6 cells and found that endogenous TR4 displays three bands. The addition of CIP to cytosolic extracts reduced the number of TR4 bands to the fastest moving component ([Fig. 1*B*](#F1){ref-type="fig"}), suggesting that TR4 is a phosphoprotein and a potential target for AMPK.

![AMPK inhibits TR4 transactivation through TR4 protein phosphorylation. *A*: Mouse, human, and rat TR4 amino acid sequence of the putative AMPK phosphorylation site. *B*: TR4 phosphorylation status by immunoblot with TR4 antibodies. Hepa1--6 cell lysates were treated with CIP or with buffer as the control. *C*: TR4-wt, TR4-S351A, and TR4-S351E protein were translated in the transcription/translation system containing \[^35^S\]methionine, as described in [Supplemental Methods](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db10-0393/-/DC1). *D*: The effect of TR4-wt and mutants (S351A and S351E) on the transcriptional activity of the TR4 target gene PEPCK-Luc reporter plasmid in Hepa1--6 cells (\*\**P* \< 0.01; \**P* \< 0.05 vs. vector control). *E*: Autoradiogram of the TR4 protein phosphorylated in vitro by AMPK. TR4-wt and S351 mutants were incubated with purified rat liver AMPK and \[γ-^32^P\]ATP, in the presence or absence of AMP, as indicated. *Lane 1*: ^35^S-labeled TR4 protein. *F*: DR1 × 3-Luc reporter vector was cotransfected with TR4 in Hepa1--6 cells. After overnight recovery, the transfected cells were treated with AICAR or CpdC for 24 h, and luciferase activity was measured (\**P* \< 0.05 vs. *lane 1*). *G*: DR1 × 3-Luc reporter vector was cotransfected with TR4 and AMPK RNAi (target sequence: AMPK-a1 5′-GAATCCTGTGACAAGCACA-3′) in Hepa1--6 cells. The transfected cells were harvested after 48 h, and luciferase activity was measured (\**P* \< 0.05 vs. *lane 1*).](1493fig1){#F1}

We then mutated the Ser351 phosphorylation site of TR4 from serine to alanine (S351A) to mimic dephosphorylated TR4 and from serine to glutamic acid (S351E) to mimic phosphorylated TR4, and then we re-evaluated these modifications on TR4 transactivation. Using a luciferase reporter assay utilizing the TR4 target gene ([@B12]), *PEPCK* promoter (PEPCK-Luc), with in vitro transcription/translation system equally expressed TR4-wt, S351A, and S351E ([Fig. 1*C*](#F1){ref-type="fig"}), we found higher TR4 transactivation for the S351A protein and lower TR4 transactivation for the S351E protein compared with TR4-wt ([Fig. 1*D*](#F1){ref-type="fig"}) in Hepa1--6 cells, suggesting that phosphorylation of TR4 at S351 resulted in suppression of TR4 transactivation in vitro.

An in vitro phosphorylation assay further demonstrated that TR4 can be phosphorylated by AMPK in the presence of AMP (TR4-wt could be phosphorylated at Ser351) ([Fig. 1*E*](#F1){ref-type="fig"}, *lane 4* vs. *3*) and that mutation of Ser351 completely abolished phosphorylation of TR4 in the presence or absence of AMP ([Fig. 1*E*](#F1){ref-type="fig"}, *lanes 5--8*). This result suggested that AMPK is an upstream signal capable of modulating TR4 protein via phosphorylation of TR4 at Ser351.

We next tested whether modulating AMPK activity, via its activator AICAR or inhibitor CpdC, resulted in the modulation of TR4 transactivation. Inactivation of AMPK via CpdC, leading to dephosphorylation of AMPK ([@B17]), resulted in enhanced TR4 transactivation on the DR1 × 3-Luc reporter, which contains TR4RE ([Fig. 1*F*](#F1){ref-type="fig"}). In contrast, activation of AMPK by AICAR resulted in suppression of TR4 transactivation ([Fig. 1*F*](#F1){ref-type="fig"}). Furthermore, reducing endogenous AMPK in hepatocytes by AMPK-RNA interference (RNAi) (a gift from Dr. J.P. Bolanos, Department of Biochemistry and Molecular Biology, University of Salamanca, Salamanca, Spain) induced TR4 transactivation ([Fig. 1*G*](#F1){ref-type="fig"}). Together, results from [Fig. 1*A*--*G*](#F1){ref-type="fig"} demonstrate that hepatic TR4 is a target of AMPK and that changing AMPK activity may modulate TR4 transactivation via reversible phosphorylation at the Ser351 site.

Metformin induces AMPK-mediated TR4 phosphorylation with decreased TR4 transactivation. {#s18}
---------------------------------------------------------------------------------------

Metformin has been used widely as an antidiabetes agent, and it activates AMPK. In vitro studies ([@B18],[@B19]) suggest that AMPK inhibits some metabolic gene expressions, for example *PEPCK* and *SCD1*. The underlying mechanisms that link metformin, AMPK, and TR4, and how they influence each other, remain unclear. Incubation of Hepa1--6 cells with metformin resulted in increased phosphorylation of AMPK at amino acid threonine 172, without changing AMPK protein expression ([Fig. 2*A*](#F2){ref-type="fig"}), which might then result in increased phosphorylation of TR4 ([Fig. 2*B*](#F2){ref-type="fig"}). The addition of CIP to metformin-treated Hepa1--6 cell lysates resulted in the disappearance of metformin-induced TR4 phosphorylation, suggesting that metformin, like AICAR, can also activate AMPK-mediated TR4 phosphorylation in Hepa1--6 cells.

![Effect of metformin on TR4 activity. *A*: AMPK and phosphor-AMPK in Hepa1--6 cells treated with metformin. *B*: TR4 phosphorylation status by Western blot. Hepa1--6 cells were treated with AICAR and metformin, and cell lysates were harvested. Cell lysates were then treated with CIP. *C*: DR1 × 3-Luc reporter vector was cotransfected with TR4 in Hepa1--6 cells. After overnight recovery, the transfected cells were treated with metformin and luciferase activity was measured (\**P* \< 0.05 vs. *lane 3*). *D*: PEPCK-Luc reporter vector was cotransfected with TR4-wt, S351A, or S351E in Hepa1--6 cells and treated with or without metformin (\**P* \< 0.05 vs. control). (A high-quality color representation of this figure is available in the online issue.)](1493fig2){#F2}

The consequence of metformin-induced AMPK-mediated TR4 phosphorylation resulted in decreased TR4 transactivation using either DR1 × 3-Luc ([Fig. 2*C*](#F2){ref-type="fig"}) or *PEPCK* promoter-Luc ([Fig. 2*D*](#F2){ref-type="fig"}). In contrast, metformin failed to repress the transactivation of TR4 mutants (TR4-S351A and S351E) ([Fig. 2*D*](#F2){ref-type="fig"}). Together, results from [Fig. 2*A*--*D*](#F2){ref-type="fig"} suggest that metformin can modulate TR4 transactivation via induction of AMPK-mediated TR4 phosphorylation.

TR4 and SREBP-1c induce *SCD1* gene expression independently. {#s19}
-------------------------------------------------------------

We noted first that SCD1 expression was markedly reduced in the liver of TR4^−/−^ mice ([Fig. 3*A* and *B*](#F3){ref-type="fig"}). The promoter-Luc assay in HepG2 cells confirmed that TR4 induced hSCD1-Luc reporter activity in a dose-dependent manner ([Fig. 3*C*](#F3){ref-type="fig"}), suggesting that TR4 can induce *SCD1* gene expression at the transcriptional level. Using a series of deletion mutations with or without putative TR4RE (a DR site with GGGGCAGGGGCA for the binding of TR4), we found that TR4 has minimal activity with the deletion mutant of *SCD1* promoter (SCD1 \[−237\]) that lost the TR4RE site ([Fig. 3*D*](#F3){ref-type="fig"}). ChIP assays further confirmed that TR4 bound directly on the *SCD1* promoter (−108 to −376) in HepG2 cells in vivo ([Fig. 3*E*](#F3){ref-type="fig"}).

![SCD1 expression and effect of TR4 on the transcriptional activity of the *SCD1* promoter. *A*: Hepatic SCD1 protein levels of TR4^+/+^ and TR4^−/−^ male mice. The Western blots are representative of 10 mice per group. *B*: Quantitative PCR using total RNAs extracted from liver of TR4^+/+^ and TR4^−/−^ mice was performed and quantified (\*\**P* \< 0.01 vs. TR4^+/+^; *n* = 6). *C*: Hep1--6 cells were cultured and transiently transfected with SCD1 reporter without or with increasing amounts of TR4-expressing wild-type plasmid (\**P* \< 0.05; \*\**P* \< 0.01 vs. *lane 1*). *D*: *SCD1* promoter full-length (−487) or deletion (−237) mutant were cotransfected with TR4 (\**P* \< 0.05 vs. *lane 1*). *E*: ChIP assay using TR4-specific antisera. *Lane 1*: Input control. *Lane 2*: Control IP with normal mouse IgG. *Lane 3*: PCR product was obtained from immunoprecipitates using TR4 antibodies. *F*: DNA pull-down assay using biotin-labeled oligonucleotides containing the PEPCK-TR4RE1, SCD1-TR4RE, and SCD1-TR4REmu. Protein extracts were incubated with biotin-labeled double-stranded oligonucleotides containing the putative TR4RE, and the bound proteins were pulled down with streptavidin-agarose beads and analyzed by immunoblotting with antibodies against TR4. A total of 25 µg of protein extract was loaded in the "input" lane as a control (*lane 1*); 100 µg of proteins were used in each pull-down (*lanes 1*--*3*, *5*, and *6*). Non--biotin-labeled oligonucleotides were used as competition probes (*lanes 4* and *7*).](1493fig3){#F3}

To determine the binding of TR4 to TR4RE in vitro, we used the nonradioactive biotin--labeled probes to perform the DNA pull-down assay. As shown in [Fig. 3*F*](#F3){ref-type="fig"}, the input control was an indication of TR4 protein; biotin-labeled probes containing SCD1-TR4RE were able to bind efficiently to TR4 ([Fig. 3*F*](#F3){ref-type="fig"}, *lane 2*). However, TR4 failed to bind to the TR4RE mutant (TR4REmu) ([Fig. 3*F*](#F3){ref-type="fig"}, *lane 5*). Thus, results from [Fig. 3*A*--*F*](#F3){ref-type="fig"} indicate that TR4 can induce *SCD1* gene expression via direct binding to the TR4RE located on the *SCD1* 5′ promoter.

Analysis of the promoter of *SCD1* found other conserved elements, including the sterol regulatory element (SRE) ([@B20],[@B21]), might be able to mediate *SCD1* induction via SREBP-1c ([Fig. 4*A*](#F4){ref-type="fig"}). *SCD1* promoter activity assay in Hepa1--6 cells demonstrated that SREBP-1c, like TR4, could also activate *SCD1* transactivation, and that the addition of both TR4 and SREBP-1c resulted in the additive transactivation effects ([Fig. 4*B*](#F4){ref-type="fig"}, *lanes 1--4*). Although SREBP-1c activation was eliminated following the mutation of the SRE (pSCD1-SREmu) reporter ([@B20]), TR4 effects persisted using pSCD1-SREmu ([Fig. 4*B*](#F4){ref-type="fig"}, *lanes 5--8*). In contrast, TR4 activation was eliminated following mutation of the TR4RE (pSCD1-TR4REmu), but the SREBP-1c effect persisted ([Fig. 4*B*](#F4){ref-type="fig"}, *lanes 9--12*). Double mutations of the SRE and TR4RE (pSCD1-[d]{.smallcaps}-mu) resulted in no *SCD1* induction in the presence of TR4 and SREBP-1c ([Fig. 4*B*](#F4){ref-type="fig"}, *lanes 13--16*), suggesting that TR4 and SREBP-1c activate *SCD1* independently.

![TR4 and SREBP-1c effects on *SCD1* gene regulation. *A*: Schematic representation of the proximal promoters of the *hSCD1*. The sequences that correspond to a SRE (■), as well as TR4RE (○) are indicated. A mutated motif is indicated (with an X). *B*: Effect of mutation of the SRE and TR4RE on the transcriptional regulation of promoter-reporter genes. Hep1--6 cells were transiently transfected with pSCD1-(−487), pSCD1-SREmu, pSCD1-TR4REmu, or pSCD1-[d]{.smallcaps}-mu, as indicated (\**P* \< 0.05; \*\**P* \< 0.01 vs. control). *C*: Hepatic *TR4*, *SREBP-1c*, and *SCD1* gene expression in wild-type mice fed with the fructose diet for 6 weeks. The relative gene expression amount was quantified by quantitative PCR (\**P* \< 0.05; \*\**P* \< 0.01 vs. control diet; *n* = 7). *D*: Hepatic *SCD1* mRNA expression upon control diet and long-term fructose feeding in TR4^−/−^ mice (\*\**P* \< 0.01 vs. control diet; *n* = 7 per group).](1493fig4){#F4}

Previous studies have shown that the *SCD1* gene is regulated at the transcriptional level by a number of dietary factors, such as glucose and fructose, via a SREBP-1c--dependent mechanism ([@B7],[@B22]), with less *SCD1* expression in normal diet--fed SREBP-1c^−/−^ mice ([@B7],[@B23]). However, long-term fructose feeding results in increased *SCD1* expression in both SREBP-1c^−/−^ and SREBP-1c^+/+^ mice, with even higher *SCD1* induction found in SREBP-1c^−/−^ mice ([@B7]). These data suggest that fructose-induced *SCD1* gene expression acts through a mechanism that is independent of SREBP-1c. In a similar series of experiments to determine whether fructose-induced *SCD1* gene expression is TR4-dependent, we found, in wild-type mice fed with a fructose diet, that *TR4*, as well as *SCD1* and *SREBP-1c* gene expression, were induced ([Fig. 4*C*](#F4){ref-type="fig"}). Increased *SCD1* gene expression was also induced by fructose in both TR4^+/+^ and TR4^−/−^ mice. It is noteworthy that TR4^−/−^ mice fed with fructose had significantly higher SCD1 gene expression compared with TR4^+/+^ mice ([Fig. 4*C* and *D*](#F4){ref-type="fig"}), and this result is similar to that obtained in fructose-fed SREBP-1c^−/−^ mice ([@B7],[@B23]). These data suggest that fructose induced *SCD1* gene expression in a TR4-independent manner. Together, results from [Fig. 4](#F4){ref-type="fig"} indicate that TR4 and SREBP-1c induce hepatic *SCD1* gene expression independently.

TR4 induces *SCD1* gene expression in the primary hepatocytes from wild-type and *db/db* mice. {#s20}
----------------------------------------------------------------------------------------------

To confirm the above results in Hepa1--6 cells showing that TR4 modulates *SCD1* gene expression, we performed transductions to deliver TR4 shRNA into Hepa1--6 cells and primary hepatocytes. Using vector-based TR4 RNA interference (pRetro-shTR4a) to knockdown TR4 expression transiently, we evaluated the effect of TR4 silencing on SCD1 reporter activity in Hepa1--6 cells. As shown in [Fig. 5*A*](#F5){ref-type="fig"}, TR4-mediated *SCD1* promoter transcriptional activation was significantly reduced in the TR4 knockdown cells ([Fig. 5*A*](#F5){ref-type="fig"}, *lane 4*). We also used mice primary hepatocytes with knockdown of TR4 (via RNAi) ([Fig. 5*B*](#F5){ref-type="fig"}). As shown in [Fig. 5*C*](#F5){ref-type="fig"}, the addition of lentiviral vector with TR4-RNAi, but not TR4-scramble-RNAi, resulted in the suppression of *SCD1* gene expression. These results are consistent with the above in vivo data.

![Inhibition of TR4 reduces *SCD1* promoter activity and gene expression. *A*: Effect of pRetro-shTR4a (TR4 RNAi) or control pRetro-shNS (scramble RNAi) on TR4-mediated SCD1-Luc activity (\**P* \< 0.05 vs. *lane 3*) in Hepa1--6 cells. The *TR4* (*B*) and *SCD1* (*C*) mRNA were quantified in TR4^+/+^ mice primary hepatocytes cultured and transiently transduced by lentiviral vector carrying pLVTHM-shTR4 (TR4 RNAi) and scramble RNAi (\**P* \< 0.05; \*\**P* \< 0.01 vs. scramble RNAi). *D*: Quantitative PCR using total RNAs extracted from liver of wild-type (WT) and *db/db* mice was performed and quantified (\**P* \< 0.05; \*\**P* \< 0.01 vs. WT; *n* = 5). *E*: Hepatic *SCD1* and *TR4* gene expression in *db/db* mice with or without metformin injection (\**P* \< 0.05 vs. control; *n* = 5). *F*: Effect of TR4 RNAi and metformin on *SCD1* mRNA amounts from primary hepatocytes (\**P* \< 0.05). NS, nonsignificant.](1493fig5){#F5}

We additionally used *db/db* mice that show induction of *SCD1* in liver ([@B24]) to confirm our finding of hepatic *SCD1* induction by TR4. As expected, we found increased expression of both *TR4* and *SCD1* in livers of *db/db* mice compared with wild-type mice ([Fig. 5*D*](#F5){ref-type="fig"}). Injection of metformin into *db/db* mice resulted in the decreased hepatic *SCD1* gene expression ([Fig. 5*E*](#F5){ref-type="fig"}) that may be a result of the decreased TR4 transactivation ([Supplementary Fig. 1A](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db10-0393/-/DC1)). We further confirmed these results via using primary hepatocytes from *db/db* mice treated with metformin in the presence or absence of TR4-RNAi. As shown in [Fig. 5*F*](#F5){ref-type="fig"}, treatment with metformin resulted in the reduction of *SCD1* gene expression in *db/db* mice ([Fig. 5*F*](#F5){ref-type="fig"}, *lanes 1* and *2*), and silencing TR4 abolished the inhibition of *SCD1* expression by metformin ([Fig. 5*F*](#F5){ref-type="fig"}, *lanes 3* and *4*), suggesting the role of TR4 in the metformin suppression of *SCD1*.

Potential pathophysiological consequences of the newly identified metformin→AMPK→TR4→SCD1 pathway. {#s21}
--------------------------------------------------------------------------------------------------

Early studies demonstrated that altered *SCD1* gene expression resulted in changes in lipid oxidative and lipogenic pathways. To dissect the consequences of TR4-induced *SCD1* expression, we compared gene profiles involved in hepatic fatty acid oxidation and lipogenesis in TR4^+/+^ and TR4^−/−^ mice. TR4^−/−^ liver showed enhanced mRNA levels of genes involved in lipid β-oxidation, carnitine palmitoyltransferase-1, acyl-CoA oxidases, and peroxisome proliferator--activated receptor-α ([Supplementary Fig. 2A](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db10-0393/-/DC1)). As expected, enhanced β-oxidation gene expression may then result in the higher rates of isolated hepatic mitochondrial β-oxidation in TR4^−/−^ mice compared with TR4^+/+^ mice, using radioisotope-labeled tracer experiments with \[U-^14^C\]palmitate ([Supplementary Fig. 2B](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db10-0393/-/DC1)).

We also examined the genes involved in hepatic lipogenic pathways. Acetyl-CoA carboxylase and fatty acid synthase were reduced in TR4^−/−^ mice liver ([Supplementary Fig. 2C](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db10-0393/-/DC1)). It is noteworthy that TR4^−/−^ mice showed no difference in *SREBP-1c-* and carbohydrate-responsive element--binding protein (*ChREBP*) expression, suggesting that the reduction of *SCD1* we observed is not a result of the loss of SREBP-1c or ChREBP in TR4^−/−^ mice ([Supplementary Fig. 2C](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db10-0393/-/DC1)).

Increased β-oxidation and reduced lipogenic gene expression via TR4-modulated *SCD1* expression in TR4^−/−^ mice may result in the lipoatrophy. Although TR4^−/−^ mice had smaller sizes and lower body weights than TR4^+/+^ mice, TR4^+/+^ and TR4^−/−^ mice had a similar basal daily food intake normalized to body weight. Epididymal and retroperitoneal fat masses of TR4^−/−^ mice were markedly reduced when these tissues were normalized by body weight compared with those of TR4^+/+^ mice ([Fig. 6*A*](#F6){ref-type="fig"}). In contrast to the dramatic reduction of white adipose tissue, other organs, such as liver, heart, kidney, and testis, were similar to those of TR4^+/+^ mice ([Fig. 6*A*](#F6){ref-type="fig"}). We also found that TR4^−/−^ mice had obvious reduction in fat-pad size ([Fig. 6*B*](#F6){ref-type="fig"}). Histological analysis showed that adipocytes of epididymal fat pads from TR4^−/−^ mice were much smaller and more heterogeneous in size than those of TR4^+/+^ mice ([Fig. 6*C*](#F6){ref-type="fig"}). Additional histological analysis showed significantly less lipid accumulation in liver from TR4^−/−^ mice via using Oil Red O staining ([Fig. 6*C*](#F6){ref-type="fig"}). Liver triglyceride level of TR4^−/−^ mice consistently was reduced to \~50% of that of TR4^+/+^ mice. However, skeletal muscle triglyceride levels were similar to that of TR4^+/+^ mice ([Fig. 6*D*](#F6){ref-type="fig"}).

![*TR4* deficiency leads to reduction of lipid content. *A*: Comparison of weights in different tissues from 10-week-old TR4^−/−^ and TR4^+/+^ male mice. The weight of each tissue was normalized by body weight. Each bar represents the means ± SD (*n* = 5). E.Fat, epididymal fat; R.Fat, retroperitoneal fat (\**P* \< 0.05 vs. TR4^+/+^). *B*: Epididymal fat pads isolated from TR4^+/+^ and TR4^−/−^ mice. *C*: Histological analyses of epididymal fat (*upper panel*) and liver (*lower panel*). Sections were stained with hematoxylin and eosin or/and Oil Red O (liver) (×400). *D*: Triglyceride contents in liver and skeletal muscle (\**P* \< 0.05 vs. TR4^+/+^; *n* = 7 per group). (A high-quality color representation of this figure is available in the online issue.)](1493fig6){#F6}

In addition to reduced fat mass, loss of the *SCD1* gene might also result in enhanced systemic insulin sensitivity ([@B25],[@B26]). We measured blood glucose and insulin concentrations and found that TR4^−/−^ mice had 10% reduction in fed and 20% reduction in fasting blood glucose concentrations, compared with those of TR4^+/+^ mice ([Fig. 7*A*](#F7){ref-type="fig"}). Serum insulin levels were lower in fed TR4^−/−^ mice, and fasting caused a decrease of insulin levels in both TR4^+/+^ and TR4^−/−^ mice ([Fig. 7*B*](#F7){ref-type="fig"}). Intraperitoneal glucose injection showed reduced blood glucose in TR4^−/−^ mice at all time periods compared with TR4^+/+^ mice ([Fig. 7*C*](#F7){ref-type="fig"}). Furthermore, blood glucose levels of TR4^−/−^ mice were returned to normal levels at 60 min after glucose injection. However, blood glucose levels of TR4^+/+^ mice were still higher than normal glucose levels until 120 min after glucose injection. Increased insulin sensitivity was further confirmed in insulin tolerance tests, showing an enhanced glucose-lowering effect in TR4^−/−^ mice compared with that of TR4^+/+^ mice ([Fig. 7*D*](#F7){ref-type="fig"}).

![TR4^−/−^ male mice show increased insulin sensitivity. Plasma concentrations of glucose (*A*) and insulin (*B*) in animals fed or fasted overnight. Values are given as means ± SD (\**P* \< 0.05; \*\**P* \< 0.01 vs. TR4^+/+^; *n* = 5--7 per group). *C*: Glucose tolerance tests. Each point represents the means ± SD (*n* = 5). *D*: Insulin tolerance tests. Each point represents the means ± SD (\**P* \< 0.05; \*\**P* \< 0.01; \*\*\**P* \< 0.001 vs. TR4^+/+^; *n* = 5--6 per group). *E*: Muscle tissue subjected to immunoprecipitation with anti-IRβ, or anti--IRS-1 antibody, followed by immunoblot analysis using antiphosphotyrosine antibody. The Western blots are representative of five separate experiments with independent tissue lysate preparations.](1493fig7){#F7}

To further examine whether increased systemic insulin sensitivity is accompanied with increased insulin signaling, we also examined insulin signaling in skeletal muscles of TR4^−/−^ and TR4^+/+^ mice. The TR4^−/−^ mice showed increased basal tyrosine phosphorylation of insulin receptor-β (IRβ) in skeletal muscle compared with TR4^+/+^ mice before infusion of insulin ([Fig. 7*E*](#F7){ref-type="fig"}), indicating that TR4^−/−^ mice are more sensitive to insulin. Both TR4^+/+^ and TR4^−/−^ mice showed insulin-induced tyrosine phosphorylation of IRβ in skeletal muscle with, as expected, a much higher extent in TR4^−/−^ mice. To further confirm increased insulin signaling in TR4^−/−^ mice, we measured tyrosine phosphorylation of insulin receptor substrate (IRS)-1. Consistent with phosphorylation of IRβ, TR4^−/−^ mice showed enhanced basal phosphorylation of IRS-1. Insulin infusion further phosphorylates IRS-1 in skeletal muscle of both TR4^+/+^ and TR4^−/−^ mice with approximately onefold higher phosphorylation of IRS-1 in TR4^−/−^ mice ([Fig. 7*E*](#F7){ref-type="fig"}; [Supplementary Fig. 1C](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db10-0393/-/DC1)).

DISCUSSION {#s22}
==========

Transactivation of nuclear receptors can be activated by ligands or via modulation through post-translational modifications, such as phosphorylation, acetylation, and sumoylation, that result in the alteration of biological function ([@B27]). Here, we found, for the first time, that transactivation of TR4 could be altered by a small molecule, such as metformin. Metformin has been shown to activate AMPK via an LKB1-dependent mechanism ([@B28]). The activated AMPK may phosphorylate TR4 and inhibit TR4 transactivation activity and subsequently downregulate TR4 target gene expression. These data suggest that TR4 activity can be altered by phosphorylation. It also provides a platform in which small molecules can change TR4 phosphorylation status in the absence of an identified ligand(s) and potentially modulate TR4 target gene expression, which show the clinical application of the physiological functions of TR4.

A previous study ([@B29]) showed that TR4 transactivation could also be modulated by mitogen-activated protein kinase phosphorylation that resulted in the recruitment of corepressors and coactivators, with hyperphosphorylated TR4 showing lower activity and hypophosphorylated TR4 showing higher activity. The same phenomena were observed in AMPK phosphorylation on TR4 proteins, that TR4 transactivation could be negatively regulated by AMPK-mediated phosphorylation. However, TR4 behavior after phosphorylation remains unclear. The AMPK phosphorylation site, Ser351, is located on the hinge region, which is important for nuclear receptor nuclear localization, suggesting that TR4 nuclear/cytosolic translocation may be regulated by AMPK phosphorylation. The impact of AMPK phosphorylation of TR4 on the DNA-binding ability, protein stability, and coregulator(s) recruitment, however, remains unclear.

The data from the SREBP-1c^−/−^ and TR4^−/−^ fructose-feeding experiments indicate that the lipogenic effects of fructose may be mediated by TR4 or SREBP-1c, whereas other transcription factors may also participate in the regulation independently. Two possible candidates mediating the SREBP-1c- or TR4-independent mechanisms are ChREBP and liver X receptor (LXR). ChREBP has been known as a transcription factor mediating glucose sensing and lipogenesis ([@B30]). However, the role of ChREBP on *SCD1* regulation is yet to be determined. LXR, the major transcription factor that activates *SREPB-1c* and *ChREBP* transcription, integrates hepatic carbohydrate and lipid metabolism ([@B31]). In a recent study ([@B32]), LXR was also identified as a transcription factor regulating *SCD1* gene expression directly. Through the LXR-response element on *SCD1* promoter, LXR could induce *SCD1* gene expression and increase the hepatic triglyceride-to-monounsaturated fatty acid-to-saturated fatty acid ratio. It has been demonstrated that the *SCD1* induction in SREBP-1c^−/−^ or TR4^−/−^ mice fed with fructose is through the SREBP-1c- or TR4-independent pathway. It is possible that the *SCD1* regulation in the absence of SREBP-1c is mediated by TR4, ChREBP, and LXR. In contrast, the induced *SCD1* gene expression in TR4^−/−^ mice may be mediated by SREBP-1c, ChREBP, and LXR. However, there is no study about the fructose or high-carbohydrate effect of *SCD1* gene expression on LXR^−/−^ or ChREBP^−/−^ mice. Therefore, the roles of ChREBP and LXR in fructose-fed SREBP-1c^−/−^ or TR4^−/−^ mice remain unclear.

Here, we showed that *TR4*-deficient mice have reduced fat-pad size, enhanced lipid oxidation, and insulin sensitivity as a result of reduced *SCD1* gene expression in liver. These metabolic changes may protect TR4^−/−^ mice from a variety of dietary and genetic conditions that promote obesity and insulin resistance. In support of this notion, SCD1^−/−^ mice were found to be resistant to diet-induced obesity, have reduced adiposity, and have increased insulin sensitivity. Furthermore, the regulation of *SCD1* gene expression is an important component of the metabolic response. The TR4^−/−^ mouse model recapitulates the phenotypes observed in standard diet--fed *SCD1*-deficient mice. In agreement with our TR4^−/−^ model, Kang et al. ([@B33]) also observed that systemic loss of TR4 results in less weight gain, lower hepatic triglyceride levels, reduced lipid accumulation in adipose tissue, and greatly decreased lipogenic gene expression. Taken together, our findings support the idea that *SCD1* may play important roles in the TR4^−/−^ mice lipid metabolism. These roles strengthen the importance of TR4 regulation on *SCD1* gene expression and the pathophysiological significance of this newly identified pathway ([Fig. 8](#F8){ref-type="fig"}).

![TR4 acts as a key regulator of *SCD1* gene expression and lipid metabolism in hepatocytes. TR4 gene expression was induced by fructose, and its activity was inhibited by AMPK-mediated phosphorylation. The binding of TR4 to the *SCD1* promoter through TR4RE motif activates *SCD1* expression and stimulates lipogenesis. (A high-quality color representation of this figure is available in the online issue.)](1493fig8){#F8}

TR4 may function as a regulator to modulate many nuclear receptor--mediated pathways, such as retinoid X receptor, retinoid acid receptor, and androgen receptor ([@B34]). Knockout of *TR4* in mice leads to growth retardation ([@B13]), as well as imbalance in glucose and lipid metabolism ([@B12],[@B15]). Recently, studies ([@B35],[@B36]) suggested that TR4 might exert its function by interacting with certain fatty acids and lipids. In general, saturated fatty acids and mono- and polyunsaturated fatty acids all show different degrees of activation of TR4. Although fatty acids are able to interact with TR4 directly, it remains possible that fatty acids may regulate TR4 activity via phosphorylation or other posttranslational modification. Because *SCD1* gene expression also can be regulated by saturated and unsaturated fatty acids, it suggests that fatty acid treatment may induce TR4 activation and TR4 target gene, *SCD1*, via a TR4-dependent pathway. The *SCD1* gene expression regulated by saturated and unsaturated fatty acids may also be involved in the TR4-independent pathway.

Together, the newly identified pathways from metformin to AMPK to TR4 in the present studies provide the first evidence showing that hepatic TR4 transactivation can be modulated by a small molecule, such as metformin, AICAR, or CpdC, which may lead to the development of a platform for using TR4 as a target to battle TR4-related diseases, such as metabolic syndrome.

This article contains Supplementary Data online at <http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db10-0393/-/DC1>.
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